Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

689
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intratumoral bicarbonate functions as an adjuvant to potentiate PD-1 blockade in hepatocellular carcinoma.

Oncogene·2026
Same author

Alkalization of cellular pH leads to cancer cell death by disrupting autophagy and mitochondrial function.

Oncogene·2022
Same author

A nonrandomized cohort and a randomized study of local control of large hepatocarcinoma by targeting intratumoral lactic acidosis.

eLife·2016
Same author

COX-2 inhibition improves immune system homeostasis and decreases liver damage in septic rats.

The Journal of surgical research·2009
Same author

Mass spectral characterization of organophosphate-labeled, tyrosine-containing peptides: characteristic mass fragments and a new binding motif for organophosphates.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·2009
Same author

3D-SURFER: software for high-throughput protein surface comparison and analysis.

Bioinformatics (Oxford, England)·2009

Related Experiment Video

Updated: May 3, 2026

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.4K

Bicarbonate-integrated transarterial chemoembolization (TACE) in real-world hepatocellular carcinoma.

Kai Jin1, Siying Zeng2,3, Bin Li1

  • 1Interventional Radiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Signal Transduction and Targeted Therapy
|August 31, 2025
PubMed
Summary

TILA-TACE offers a 99% objective response rate for hepatocellular carcinoma (HCC) local control, significantly improving upon conventional treatments. This novel therapy shows a tolerable safety profile and survival benefits, especially for advanced HCC stages.

More Related Videos

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.7K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

596

Related Experiment Videos

Last Updated: May 3, 2026

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.4K
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.7K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

596

Area of Science:

  • Hepatobiliary oncology
  • Interventional radiology
  • Radiation oncology

Background:

  • Conventional transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) has an objective response rate of approximately 50% for locoregional control.
  • TILA-TACE, a novel bicarbonate-integrated TACE, previously demonstrated 100% effectiveness in locoregional control for unresectable HCC.

Purpose of the Study:

  • To validate the efficacy, selectivity, and safety of TILA-TACE in real-world clinical practice for HCC treatment.
  • To evaluate the outcomes of TILA-TACE combined with radiation therapy for advanced HCC, including macrovascular invasion and extrahepatic metastases.

Main Methods:

  • A total of 413 patients with HCC (early, intermediate, and advanced stages) were enrolled in this real-world validation study.
  • TILA-TACE was used for primary tumor treatment, while radiation therapy was employed for macrovascular invasion and extrahepatic metastases.
  • Side effects of TILA-TACE were systematically recorded and analyzed.

Main Results:

  • TILA-TACE achieved a 99.01% objective response rate for HCC tumors, with a 72.77% complete response rate.
  • Radiation therapy demonstrated a 96.88% objective response rate for tumor thrombus.
  • Median survival for advanced-stage HCC patients was 27 months, with intrahepatic metastases being the primary cause of cancer-related death.

Conclusions:

  • TILA-TACE is a highly effective and safe novel treatment for local control of HCC, with a tolerable safety profile.
  • The combination of TILA-TACE and radiation therapy provides significant survival benefits for patients with advanced HCC.
  • Further research is warranted to address intrahepatic metastases as a cause of mortality post-treatment.